|
Arenicin is the name used to classify a group of antimicrobial peptides, which have shown promise as a novel drug to combat Gram-negative bacteria. The Arenicin family consists of three different subjects, each distinct in their structure: Arenicin-1, Arenicin-2, and the most recently discovered, Arencin-3. Arenicin-1 and Arenicin-2 were identified by a Russian research group in 2004, while Arenicin-3 was discovered by a Danish biopharmaceutical company called Adenium Biotech, which once operated within Novozymes A/S.〔Neve, S., Raventós, D., et al. ("NZ17074 : An Arenicin-3 variant found by HTS screening of yeast libraries" ). Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.〕 Given the growing acquisition of multidrug resistance among bacterial pathogens, particularly in Gram-negative bacteria, the development of Arenicin as a novel drug treatment has been under way. Arenicin-3 has been of particular interest in the fight against urinary tract infections caused by E. coli strains. It is also being developed with the intention of treating hospital acquired infections. In both applications, there are two proposed modes of action by which Arenicin-3 interacts with the bacteria.〔Adenium Biotech Aps. EP2509617A1, 2012, ("Arenicin-3 for use in the treatment of urinary tract infections" )〕 Adenium Biotech currently remains in the preclinical testing period of their product, Arenicin-3. Toxicology, drug efficacy, and other information have yet to be determined with further research completed in clinical settings. However, with Gram-negative bacteria causing 65% of hospital-acquired infections, the commercial market for Arenicin is large.〔("Adenium Biotech" ). Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.〕 ==Background (Discovery and Development)== The drug Arenicin was discovered by the company Adenium Biotech, which spun off from Novozymes A/S in 2011 and was given funding support from NovoSeeds and Sunstone Life Science Ventures Fund III.〔("Adenium Biotech" ). Novozymes A/S. Copenhagen: Adenium Biotech, Web. 29, Nov. 2012.〕 The compound was initially found in secretions from the lugworm, and is part of its defense against invasive bacteria.〔("Arenecin" ). Novozymes A/S. Copenhagen: Adenium Biotech, Web. 29, Nov. 2012.〕 Adenium Biotech currently holds patents for Arenicin’s use against urinary tract infections.〔 Arenicin is currently in the pre-clinical trial development phase. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Arenicin」の詳細全文を読む スポンサード リンク
|